Story thread · 2 reports / 2 sources
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
financialpost.com · 13d
MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, […]
First report: Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia — thestar.com, 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.